Evaluation of T-subsets and NK cell activity in patients with superficial bladder cancer after intravesical treatment with bacillus calmette-guerin.
- Author:
Sang Cheol LEE
1
;
Ja Hun LEE
;
Sung Goo CHANG
;
Soo Eung CHAI
Author Information
1. Department of Urology, School of Medicine, Kyung Hee University, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Superficial bladder tumor;
Bacillus Calmette-Guerin;
Cellular immune response
- MeSH:
Administration, Intravesical;
Bacillus*;
Humans;
Immunity, Cellular;
Killer Cells, Natural*;
Mycobacterium bovis;
Recurrence;
Urinary Bladder Neoplasms*;
Urinary Bladder*
- From:Korean Journal of Urology
1992;33(2):200-205
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Intravesical instillation of Bacillus Calmette-Guerin(BCG) currently is considered the most effective treatment for recurrent superficial bladder cancer, but little is known about the mechanism of action. Total 21 patients receiving intravesical BCG treatment for superficial bladder cancer were entered into this study to investigate the cellular immune response with T-subsets and NK cell activity in peripheral blood before and after intravesical BCG instillation consisted of weekly administration with BCG for six consecutive weeks. Among the 21 patients. 11 had Grade 1 and 10 had Grade 2 bladder cancer and 14 of them had history of recurrence more than 2 times. The results showed that there were no significant differences in the changes of CD4 cell. CD8 cell as T- subsets and NK cell activity before and after treatment(P greater than 0.06 in all). Among 7 patients with recurrence after BCG treatment, there was also no difference in any immune response (P greater than 0.05 in all). Considering the response of the individual patients. We observed that recurrence rates were similar between a group containing the patients with increased value more than 20% after treatment and other in all immune parameters such as CD4. CD8, CD4/CD8 ratio and NK cell activity(P greater than 0.0S in all). We conclude that these parameters are not major contributors to the antitumor activity of BCG and had no prognostic value for the clinical outcome after BCG treatment.
